Research programme: erythropoietin dimer - Beth Israel Deaconess Medical Center/DNAPrint Genomics
Alternative Names: PT-401; Super EPO dimerLatest Information Update: 16 Jul 2016
At a glance
- Originator Beth Israel Deaconess Medical Center
- Class Erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anaemia in USA
- 09 Apr 2008 Pharmacodynamics data from a preclinical study presented at the 109th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2008)
- 05 Apr 2005 Preclinical trials in Anaemia in USA (unspecified route)